We focus far too much on the chronological finish line. Death is just a trailing indicator. The real metric—the one that dictates civilizational cost and individual quality—is the latent period of physiological integrity. Why does one person maintain a youthful phenotype until 80 while another starts the descent at 50?

I see two competing ideas for what constitutes the "first domino" in chronic disease.

The first is the Steroidogenic Kinetic Bottleneck. This suggests the onset of disease is driven by the velocity of cholesterol translocation. Once the StAR protein slows down and Leydig cell mitophagy fails, the hormonal environment collapses, opening the door for metabolic syndrome and neurodegeneration. In this framework, aging is a supply-side failure; the body simply runs out of the fuel required for homeostasis.

The second is the Autonomic Withdrawal Theory. This posits that chronic disease is actually a downstream symptom of neural orphanhood. When autonomic nerves retreat from a tissue—be it the vasculature, the heart, or the gonads—the resulting TGF-β1 surge triggers a myofibroblast transformation. The organ doesn’t just "age." It’s structurally re-written into a non-functional scar because it lost its trophic tether.

I’m betting on the latter. In almost every age-related pathology, the nerve fails to command before the cell fails to produce. If you lose autonomic trophic support, the kinetics of the StAR protein won’t matter because the tissue has already opted for fibrotic stasis. Denervation is the silent signal that tells the body it’s no longer in the game.

We have to stop using mortality as our primary endpoint in clinical trials. It’s a lazy, low-resolution variable that ignores the twenty-year lead-up to the collapse. Instead, we should be funding high-resolution mapping of the neuro-epithelial junction in middle age. If we can prevent that initial denervation event, we don’t just extend life; we compress the period of morbidity into a rounding error.

I’m currently looking for collaborators with expertise in in vivo optogenetics to test if sustained autonomic firing can override the fibrotic program in aging gonadal tissue. The signal is the solution.